Expression and significance of p53 and mdm2 in patients with leukoplakia cancer

Cui, Juanjuan; Han, Xiao-Lan; Wang, Weimin

doi:10.1016/s1995-7645(13)60147-9

Cited by 3 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Artificial disruption of this complex in cultured cells is enough to invoke p53-mediated gene expression and cell-cycle arrest MDM2 in response to DNA damage. So over expression levels of MDM2 decrease p53 protein levels and function, leading to gene amplification, accelerated tumor formation and progression [12,[21][22][23]25,26] . Minichromosome Maintenance -3 proteins (MCM3) are proliferation proteins have gained special interest to predict the biological, clinical behaviors (prognosis) and diagnose of various pathologic lesions [13,14] .…”

Section: Discussionmentioning

confidence: 99%

The controversial role of MDM2, MCM3 and Bcl-X in Ameloblastoma and Ameloblastic Carcinoma: An update

Salama

Hany

Esmaeil

2022

Egyptian Dental Journal

View full text Add to dashboard Cite

Background: Although great strides were made toward understanding the pathogenesis of ameloblastoma, the malignant transformation potential remains understudied. This study introduces an updated view on the involvement of MDM-2, MCM-3, and Bcl-X in ameloblastoma variants and ameloblastic carcinoma.Aim: This study aims to investigate the etiopathogenesis controversial role of MDM-2, MCM-3, and Bcl-X in ameloblastoma variants and ameloblastic carcinoma.Methodology: Forty cases were included in the current study, thirty cases of ameloblastoma and ten cases of ameloblastic carcinoma that were immunohistochemically stained for MDM-2, MCM-3, and Bcl-X antibodies.Results: Statistically significant positive expression of MDM-2, MCM-3, and Bcl-X in ameloblastic carcinoma than ameloblastoma variants. Positive expression was highly detected in conventional, ameloblastoma than unicystic ameloblastoma. Conclusion:Immunoreactivity for MDM-2, MCM-3, and Bcl-X in ameloblastoma variants and ameloblastic carcinoma suggests that these antibodies might be associated with tissue structuring and cytodifferentiation of ameloblastomas and aggressiveness of ameloblastic carcinoma. High levels of MCM-3 and MDM-2 proteins expression are more sensitive in predicting growth rate of tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

The controversial role of MDM2, MCM3 and Bcl-X in Ameloblastoma and Ameloblastic Carcinoma: An update

Salama

Hany

Esmaeil

2022

Egyptian Dental Journal

View full text Add to dashboard Cite

show abstract

“…This explained by the fact of MDM2 mainly exerts its activity by downregulating the P53 tumor suppressor gene activity and its product. So high expression levels of MDM2 decrease p53 protein levels and function, leading to accelerated tumor formation and progression (35) .…”

Section: Discussionmentioning

confidence: 99%

Association of Cortactin and MDM2 in Solid Ameloblastoma and its Malignant Counterpart

Radi

2019

Egyptian Dental Journal

View full text Add to dashboard Cite

Ameloblastoma is characterized by heterogeneity regarding its pathogenetic development, molecular abnormalities, and clinical course. Determining the molecular basis underlying these important differences remains challenging. Nevertheless, identifying molecules that influence tumor behavior would be the first steps towards gaining some insights into its pathobiology. MDM2, a 90-95kDa protein coded by a mdm2 gene which is mapped on chromosome 12q13-14. MDM2 is a negative regulator of p53 activity, through binding to the transcriptional activation domain of p53 leading to proteasome-mediated degradation, Cortactin, a product of CTTN gene, mapped to human chromosome 11q13 regulates actin-related (Arp2/3) complex induction of actin polymerization during invadopodia formation, thereby promoting cell motility. This has been accomplished through its involvement in all steps of the invadosome lifecycle, from the assembly, maturation, proteolytic activity, and disassembly. This study aims to evaluate the association of both MDM2 and Cortactin expression in solid ameloblastoma and its malignant counterpart and analyzing their significance. 10 cases of SAB with its different histologic variants and 20 cases malignant variants of ameloblastoma tumors were collected. An immunohistochemical investigation using, Cortactin, and MDM2 antibodies were done for all specimens. There was a statistically significant difference between malignant group and benign group. According to the current study Cortactin and MDM2 can be useful when considering the diagnosis of malignancy.

show abstract

“…Another tumor marker, p53, was reported upregulated in leukoplakia, and approximately 1.6% of leukoplakia cases were p53 positive. Moreover, oral cancer developed from leukoplakia showed an increased p53 positive status with a rate of 3.4% ( Cui et al, 2013 ). The p53 expression rate and intensity were reported to be higher in the high-grade group in comparison to the low-grade group with a higher lymph node metastatic potential than p53 negative cancer ( Cui et al, 2013 ; Okoturo et al, 2018 ).…”

Section: Oral Potentially Malignant Disordersmentioning

confidence: 99%

“…Moreover, oral cancer developed from leukoplakia showed an increased p53 positive status with a rate of 3.4% ( Cui et al, 2013 ). The p53 expression rate and intensity were reported to be higher in the high-grade group in comparison to the low-grade group with a higher lymph node metastatic potential than p53 negative cancer ( Cui et al, 2013 ; Okoturo et al, 2018 ). Other molecular markers also, at the tissue level, showed alternation as atypical (hyperplastic and dysplastic) conditions arose in the oral epithelium.…”

Section: Oral Potentially Malignant Disordersmentioning

confidence: 99%

Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer

2022

View full text Add to dashboard Cite

show abstract

Expression and significance of p53 and mdm2 in patients with leukoplakia cancer

Abstract: The positive rate of p53 and mdm2 cells in the peripheral blood increases in patients with leukoplakia cancer tissue and has positive correlation with the severity of leukoplakia cancer.

Cited by 3 publications

References 2 publications

The controversial role of MDM2, MCM3 and Bcl-X in Ameloblastoma and Ameloblastic Carcinoma: An update

The controversial role of MDM2, MCM3 and Bcl-X in Ameloblastoma and Ameloblastic Carcinoma: An update

Association of Cortactin and MDM2 in Solid Ameloblastoma and its Malignant Counterpart

Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer

Contact Info

Product

Resources

About